

# Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares

NCT07346079

---

Status	RECRUITING
Phase	Phase 4
Sponsor	Massachusetts General Hospital
Enrollment	150 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- Signed informed consent to participate in this study
- Male and female patients, aged 18-85 years
- Meeting the 2015 Gout classification criteria of the ACR/EULAR collaborative initiative
- Onset of current acute gout flare within 5 days prior to study entry
- Body mass index of less than or equal to 45 kg/m<sup>2</sup>

... and 6 more (see full listing online)

### Exclusion (14)

- Patients with scleroderma, osteoporosis, active or recurrent bacterial, fungal or viral infections, ocular herpes simplex, recent surgery (within 2 weeks prior to randomization or have an unhealed operation wound(s)), history of or the presence of a peptic ulcer, uncontrolled congestive heart failure, uncontrolled hypertension, uncontrolled diabetes type 1 or 2, or sensitivity to proteins derived from porcine sources.
- Patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.
- Rheumatoid arthritis, evidence or suspicion of infectious/septic arthritis, or other acute inflammatory arthritis.
- Polyarticular gouty arthritis involving more than 4 joints.
- Participation in another concurrent investigational study within 30 days of randomization or has taken an investigational drug within five times the half-life of that investigational drug has passed.

... and 9 more (see full listing online)

## Locations (1 total)

---

Mass General Hospital, Boston, Massachusetts, United States